SOPH
SOPHiA GENETICS SA
Healthcare — Health Information Services
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom. The company was incorporated in 2011 and is based in Rolle, Switzerland.
Price History
Fundamentals
| Market Cap | $463.94M |
| P/E Ratio (TTM) | - |
| Forward P/E | -9.88 |
| EPS (TTM) | $-1.18 |
| Dividend Yield | - |
| Profit Margin | -99.70% |
| Revenue Growth | 22.00% |
| ROE | -123.28% |
| Debt/Equity | 136.63 |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $8.00 |
| Analysts | 3 |
| Next Earnings | Aug 4, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 57.3 |
| Beta | 0.99 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $6.30 |
| 52-Week Low | $2.81 |
| 50-Day Avg | $5.11 |
| 200-Day Avg | $4.76 |
| Avg Volume | 298.2K |
| Volume | 963.7K |
Performance Analysis
NEUTRALSOPH presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:32 UTC
Back to Screener Export Report